March 8, 2022
Platform Lead, Cancer Databases & Tissue Banks, Singapore Translational Cancer Consortium;
Senior Consultant (Medical Oncology), National Cancer Centre Singapore (NCCS);
Director of Research, Clinical Analytics, Division of Medical Oncology, NCCS, Singhealth;
Senior Clinician Scientist, Genome Institute of Singapore, A*Star
Assoc. Professor Iain Tan is a Senior Consultant Medical Oncologist, leading the colorectal cancer service in the GI Oncology Team at the Department of Medical Oncology, National Cancer Centre Singapore. He co- chairs Singhealth’s multidisciplinary colorectal cancer tumor board. Nationally, he chairs the Medical Oncology Exit Exam committee for specialist accreditation & is a member of MOH’s research training review panel & NMRC’s grant review panel. At NCCS, he is also the clinical chair for NCCS’s luminal GI cancer Comprehensive Research Program. Concurrently, he is a clinician scientist at Genome Institute of Singapore and an assistant professor at Duke-NUS. His research focuses –on metastases and drug resistance and immune-oncology in gastrointestinal cancers, with a special interest in non-invasive diagnostics & innovative early phase clinical trials. He has published widely, with many first or corresponding authorpublications in leading journals including Journal of Clinical Oncology, Nature Medicine, Nature Genetics, Science Translational Medicine and Lancet Oncology. For his research, he has received the ASCO Young Investigator Award (2010) and ASCO Merit Award (2011) and Singhealth Distinguished Young Researcher Award. For his clinical service & research, he received the Singapore Youth Award in 2014, the country’s highest award for youths.
SINGAPORE, 7 July 2022 – MiRXES Pte Ltd, a Singapore-headquartered biotechnology company, whose mission is to save and improve lives through early, actionable, and personalized diagnoses with its innovative RNA-powered cancer early detection solutions, announced today the signing of a Memorandum of Understanding (MOU) that launched Project CADENCE (CAncer Detected Early caN be CurEd). Project CADENCE is the world’s first large-scale clinical research project for the discovery and validation of novel combinations blood-borne circulating microRNA (miRNA) and DNA methylation biomarkers that will lead to the development of a multi-cancer early detection test for up to nine high incidence and high mortality cancers, including lung, breast, colorectal, liver, stomach (gastric), esophageal, ovarian, pancreatic, and prostate cancers.
A new national consortium – the Consortium for Clinical Research and Innovation, Singapore (CRIS) – has been officially launched by the Minister for Health Mr Ong Ye Kung on 6 April 2022 CRIS brings together five key national R&D, clinical translation and service initiatives that will advance clinical research and innovation for Singapore, and establish important capabilities for a future-ready healthcare system